Kisha Mitchell Selected Research

Octreotide (Sandostatin)

3/2010

Amelioration of symptoms and reduction of VIP levels after hepatic artery chemoembolization in a patient with sandostatin resistant VIPoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kisha Mitchell Research Topics

Disease

2	Neoplasms (Cancer) 01/2016 - 05/2014
1	Adenocarcinoma 01/2021
1	Pathologic Complete Response 01/2021
1	Esophageal Neoplasms (Esophageal Cancer) 01/2021
1	Colorectal Neoplasms (Colorectal Cancer) 04/2013
1	Hypertriglyceridemia 01/2013
1	Insulin Resistance 01/2013
1	Diarrhea 03/2010
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 03/2010
1	Hypokalemia 03/2010
1	Islet Cell Adenoma (Islet Cell Tumors) 03/2010
1	Vipoma (WDHA) 03/2010
1	Dehydration (Water Stress) 03/2010

Drug/Important Bio-Agent (IBA)

1	Biomarkers (Surrogate Marker)IBA 01/2021
1	Contrast MediaIBA 01/2016
1	GadoliniumIBA 01/2016
1	gadolinium ethoxybenzyl DTPA FDA Link 01/2016
1	DNA (Deoxyribonucleic Acid)IBA 05/2014
1	LipidsIBA 01/2013
1	FructoseIBA 01/2013
1	Insulin (Novolin)FDA Link 01/2013
1	Octreotide (Sandostatin)FDA LinkGeneric 03/2010
1	Vasoactive Intestinal Peptide (VIP (Vasoactive Intestinal Peptide))IBA 03/2010

Therapy/Procedure

2	Therapeutics 01/2021 - 05/2014
1	Combined Modality Therapy 01/2021
1	Drug Therapy (Chemotherapy) 01/2021
1	Neoadjuvant Therapy 04/2013